Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression as... - PubMed - NCBI

Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression as... - PubMed - NCBI

J Surg Oncol. 2017 Feb 17. doi: 10.1002/jso.24561. [Epub ahead of print]

Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.

Hyams DM1, Schuur E2, Angel Aristizabal J3, Bargallo Rocha JE4, Cabello C5, Elizalde R6, García-Estévez L7, Gomez HL8, Katz A9, Nuñez De Pierro A10.

Author information

Abstract

Risk stratification of patients with early stage breast cancer may support adjuvant chemotherapy decision-making. This review details the development and validation of six multi-gene classifiers, each of which claims to provide useful prognostic and possibly predictive information for early stage breast cancer patients. A careful assessment is presented of each test's analytical validity, clinical validity, and clinical utility, as well as the quality of evidence supporting its use.

© 2017 The Authors. Journal of Surgical Oncology Published by Wiley Periodicals, Inc.

KEYWORDS:

adjuvant; biomarkers; breast neoplasms; chemotherapy; clinical decision-making; gene expression; genomics risk; prognosis; tumor

PMID:

 

28211064

 

DOI:

 

10.1002/jso.24561